Enhancement of therapeutic protein in vivo activities through glycoengineering. - sprookjes - yvandenbroek - TriplyDB

Enhancement of therapeutic protein in vivo activities through glycoengineering.

Enhancement of therapeutic protein in vivo activities through glycoengineering.

http://www.wikidata.org/entity/Q34180647

about

Agrarian diet and diseases of affluence--do evolutionary novel dietary lectins cause leptin resistance?Erythropoietin and diabetes mellitus Physiology and pharmacology of erythropoietin Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit Glycotherapy: new advances inspire a reemergence of glycans in medicine Engineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of Biotherapeutics Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin Engineering of complex protein sialylation in plants.Effects of localized interactions and surface properties on stability of protein-based therapeutics.Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry.Peptide aptamers: recent developments for cancer therapy.A new strategy for the synthesis of dinucleotides loaded with glycosylated amino acids--investigations on in vitro non-natural amino acid mutagenesis for glycoprotein synthesis.Purification, cloning, and expression of an alpha/beta-galactoside alpha-2,3-sialyltransferase from a luminous marine bacterium, Photobacterium phosphoreum.Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.Development of neuropeptide drugs that cross the blood-brain barrier.Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.Chemical glycosylation of cytochrome c improves physical and chemical protein stability.Integrating bioinformatics tools to handle glycosylation The sweet tooth of bacteria: common themes in bacterial glycoconjugates.Glyco-modification of protein with O-cyanate chain-end functionalized glycopolymer via isourea bond formation Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein.Generation of biologically active multi-sialylated recombinant human EPOFc in plants.Erythropoietin after a century of research: younger than ever.Survival and proliferative roles of erythropoietin beyond the erythroid lineage.Pharmacokinetics and pharmacodynamics of recombinant human EPO-Fc fusion protein in vivo Structural and histological characterization of oviductal magnum and lectin-binding patterns in Gallus domesticus Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.The influence of artificially introduced N-glycosylation sites on the in vitro activity of Xenopus laevis erythropoietin.Molecular basis of S-layer glycoprotein glycan biosynthesis in Geobacillus stearothermophilus Development of secreted proteins as biotherapeutic agents.Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody.XBP1s Links the Unfolded Protein Response to the Molecular Architecture of Mature N-Glycans Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies.In silico design and analysis of a new hyperglycosylated analog of erythropoietin to improve drug efficacy.Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration Recent developments in the production of human therapeutic proteins in eukaryotic algae.A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner.

P2860

Q21256397-1BB364EA-7E5A-424B-9762-083212B5DE7F Q26777878-D1B370CC-063F-4073-899B-F9F3B9F0E196 Q26866945-83377F96-B06B-4CCA-BC52-945FCC031DCB Q26999850-9C01E07B-3F53-4102-AC6C-74B5EE8A0350 Q27027997-57072D45-4736-478E-A3F3-3B8F22D10A1D Q27677555-63235FFA-62C9-4DBB-8260-2A82982F5BBA Q28542564-3F07CEB7-AB2D-419D-A3DC-AC1EBC805259 Q30313981-1DD5D1E8-C938-4FB6-B867-CD5503B51721 Q30395368-F33FC521-38DD-4EF4-B2D0-DA13CC9C1233 Q33211610-5D512BB3-CD17-4694-BD2C-2366823C318C Q33216999-31714758-FC61-4CD7-B8BD-5AF2E1FDAC46 Q33222834-9C2B5E6E-53B3-4FF7-A6C2-8DF39241664B Q33294323-77D49912-E3A8-48CD-B2F7-173A4C9C2EDA Q33494136-3B57553F-D204-48B1-88C2-61D5333A0138 Q33569277-CF086597-4DD5-4E11-990A-7951FFD175BF Q33586660-CD8E033B-CB11-4373-8782-2AD85F79FB9C Q33804787-80E1BD28-3F54-45F7-AE9E-112545ECBB78 Q34034670-1484ED56-397B-481E-B419-A4E95493CE49 Q34062756-F173D401-EED6-4579-812F-D3094E157684 Q34118984-B66EE649-2B9A-43A2-9E6B-6EA76D4ED26D Q34297837-4DD00D78-37E9-467C-B5DA-51971C88FFBA Q34535084-CE41C109-328D-4225-936B-948563812614 Q34545655-AB8A5DD4-9E9E-449B-880B-CB0CFFCD1D20 Q34571378-3C90B084-0199-4323-820E-18E41E6893C1 Q34606348-E77B88A6-01A0-4F59-8124-362AE1251C7D Q34725972-80A01B6E-EF49-4A2C-8E53-22C7408AA6D3 Q34974011-9F143CF8-D88E-4214-86EC-4D5B865CA1D9 Q35044418-7134C570-06CF-4935-8845-622C50ECCA2A Q35129041-C0FB9D09-A3A6-4F8D-82F4-68D72FD99F0C Q35144050-AF98CEA6-DFAB-408C-997B-B06B1CDDD4B9 Q35610754-97711D83-FD8B-41BB-BEB6-72C446DE0048 Q35674532-84EB31B1-B98A-4CAF-9B82-90968A34C237 Q35753538-E5F2C6BB-3A6B-4641-BE23-CDBE75344BB2 Q35812440-11C12721-A096-40BA-839D-A12DA3CFFC23 Q35819259-F168E1FC-08A1-4B78-A8E3-60E09D099A10 Q35990992-4EFED79B-1FA9-458B-9A76-644520E6DB1C Q35997019-7E2E3FD4-520F-4EC2-8C11-FCE245231296 Q36025060-360F47BE-7171-4FBE-B68F-D8826387C43F Q36065964-F30D977E-FD54-4255-8917-60157DB5396B Q36174711-20B06AC1-7185-4B04-BCC9-F3FB9563C6B7

P2860

Enhancement of therapeutic protein in vivo activities through glycoengineering.

http://www.wikidata.org/entity/Q34180647

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@ast

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@en

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@nl

type

label

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@ast

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@en

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@nl

prefLabel

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@ast

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@en

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@nl

P1433

Q34180647-989B9E4C-9DF3-4EEF-990B-E6EB3F8098E8

P1476

Q34180647-647A07EA-2A3C-4F72-A110-56969C72FB8A

P2093

Q34180647-0514E723-FE31-4B96-8C8D-1238641C7EC4

Q34180647-0909BA9B-D9C4-4526-A72D-BC54AD06CD56

Q34180647-0FAF2109-805C-445A-AED8-FC6F89C49876

Q34180647-12471052-F9E8-4FEE-8414-5B35D3FD71A4

Q34180647-3EDAA33E-D536-4E56-9CAA-36E545522A56

Q34180647-43AD97E3-BEA6-4190-B7B4-EC338039EDE8

Q34180647-46DE36BC-20EC-4CCE-BC37-65902680D7DF

Q34180647-6403CC48-12F2-469E-BC32-750B6255CE77

Q34180647-642273FF-D2C2-4B71-B07D-D39210D9CDD8

Q34180647-76FA1583-F581-4736-A76F-1CD1D11B55EB

P2888

Q34180647-62AE895B-402E-4197-B620-CD81FA113CC6

P304

Q34180647-78650921-939C-4824-95C0-F94F2695E315

P31

Q34180647-545211DB-44A6-47DE-9B66-EA1BCA529F0B

P356

Q34180647-2A87689E-1E7E-4508-8BAF-32674A99A20A

P433

Q34180647-B711A6B8-1487-46EE-9D1B-FE3D6B41D702

P478

Q34180647-EE3DB99C-2F2C-4ECA-BDB6-C4D333B81E0E

P577

Q34180647-EF4387C6-1837-4523-B1E4-071AEF7370DF

P698

Q34180647-C8E74397-B342-4BEC-A3F1-8A3C2789DD00

P356

P1433

Nature Biotechnology

P1476

Enhancement of therapeutic protein in vivo activities through glycoengineering.

@en

P2093

Andrew Knudten

http://www.w3.org/2001/XMLSchema#string

David Brankow

http://www.w3.org/2001/XMLSchema#string

David Chang

http://www.w3.org/2001/XMLSchema#string

Frank Martin

http://www.w3.org/2001/XMLSchema#string

Gary Rogers

http://www.w3.org/2001/XMLSchema#string

Geri Trail

http://www.w3.org/2001/XMLSchema#string

James Grant

http://www.w3.org/2001/XMLSchema#string

Janis Fuller

http://www.w3.org/2001/XMLSchema#string

Joan Egrie

http://www.w3.org/2001/XMLSchema#string

Ken Aoki

http://www.w3.org/2001/XMLSchema#string

P2888

P304

414-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT799

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12612588

http://www.w3.org/2001/XMLSchema#string